Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$44.63 USD
+0.18 (0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $44.62 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
TNDM 44.63 +0.18(0.40%)
Will TNDM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNDM
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Other News for TNDM
Embecta Corp.: Navigating Through A Changing Landscape
Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin
Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union
Three Buys, three Sells, one Hold by Oppenheimer analysts
Three ‘buys,’ three ‘sells,’ and a ‘hold,’ by Oppenheimer analysts